Citi

There may not be anything wrong with Charles Schwab Corp (NYSE: SCHW)’s business, but one Wall Street analyst says there’s plenty wrong with the stock’s current share price. The Analyst Citi analyst William Katz downgraded Charles Schwab from Neutral to Sell and lowered his...

The market’s historic sell-off on Monday certainly got the attention of investors. It also got the attention of market experts and analysts, many of whom took the opportunity to weigh in on what the sell-off means and how traders should react. Here’s a rundown of what Wall Street had to...

Citi turned bullish on BlackRock, Inc. (NYSE: BLK) back in 2016, but the firm said its case for being aggressive on the stock no longer applies. The Analyst Citi's William Katz downgraded BlackRock's stock rating from Buy to Neutral with an unchanged $625 price target. The Thesis Citi...

Esperion Therapeutics Inc (NASDAQ: ESPR) is finishing research on its bemepedoic acid for lipid management, and while the Street expects success, the drug’s potential is weighted by a dearth of interested buyers. The Rating Citi analyst Joel Beatty downgraded Esperion to Neutral, but raised...

Shares of Juno Therapeutics Inc (NASDAQ: JUNO) soared higher by 50 percent Wednesday after reports surfaced that the company is being targeted by Celgene Corporation (NASDAQ: CELG) for an acquisition. Here's what some of Wall Street's top analysts are saying. Morgan Stanley: Deal Could...

The internet sector was a major winner throughout 2017 and some Wall Street analysts are expecting more of the same in 2018. The Analyst Citi's Mark May maintained a Buy rating on the following stocks, with price targets revised higher: Amazon.com, Inc. (NASDAQ: AMZN): price target...

Aftera huge runup since its September IPO, it's only natural for some Wall Street analysts to start suggesting investors sell Roku Inc (NASDAQ: ROKU) and pocket their gains. The Analyst Citi's Mark May downgraded Roku's stock from Neutral to Sell, with a price target raised from...

FedEx Corporation (NYSE: FDX) hit a new all-time high of $253.24 after the company handily exceeded Wall Street's expectations in its fiscal second quarter earnings report. Here is a summary of how some of the Street's top analysts responded to the print. Bank Of America: Solid Quarter...

Shares of Micron Technology, Inc. (NASDAQ: MU) is trading up Wednesday after delivering a top- and bottom-line beat in its fiscal first quarter earnings report. Micron guided its fiscal second quarter notably above Street estimates. Here's how Wall Street reacted.  Citi: Micron Has The...

Dicks Sporting Goods Inc (NYSE: DKS) could get back in the game in 2018. The sporting goods retailer has had little to celebrate in 2017, with shares down 44 percent year-to-date, amid a rapidly changing industry and a heavily promotional environment. A new sell-side report projects that Dicks will...

Foot Locker Inc (NYSE: FL) has done the unthinkable. After suffering through an abysmal 2017, the footwear retailer has climbed to the top of Citi’s Buy list for 2018. The Analyst Kate McShane of CitiBank reiterated a Buy rating on Foot Locker and raised the price target from $47 to $...

Is retail making a comeback? It may be too early to say, but analysts at Citi at the very least expect concerns to "subside in a meaningful way" in 2018. The Analyst Citi's Kate McShane and Geoffrey Small. The Thesis The tremendous growth of e-commerce and the rise of Amazon.com,...

Novavax, Inc. (NASDAQ: NVAX), a small-cap clinical-stage vaccine company that focuses on therapies for both known and newly emerging diseases, has lost some support from a Wall Street analyst. The Analyst Citi's Joel Beatty downgraded Novavax's stock from Buy to Neutral. The Thesis...

2017 was a good year for Apple Inc. (NASDAQ: AAPL) investors given a near 50 percent return and the stock trading close to its all-time highs. Many among Wall Street are expecting 2018 to be just as rewarding to investors. The Analyst Citi's Jim Suva maintains a Buy rating on Apple's...